Guest guest Posted June 9, 2005 Report Share Posted June 9, 2005 Bristol-Meyers Squibb has signed the BMS Petition and here is their comment: Hooray CMLers.............. Squibb Bristol-Myers Squibb recognizes that the criteria specified in our Phase II protocols are not applicable to some patients. Therefore, in consultation with CML experts and global regulatory authorities, we are already implementing several additional Phase II clinical trial protocols that will permit entry of a broader group of patients across all phases of CML who are either resistant, refractory, or intolerant of imatinib therapy. These studies have been submitted to a large number of investigators across six continents and will address the concerns raised in this petition. Once approved by each institution's IRB (Institutional Review Board), the trial information will be posted on ClinicalTrials.gov. In the meantime, patients looking for information regarding eligibility and enrollment in current dasatinib trial programs can call Bristol-Myers Squibb's toll-free number at 1- 877-526-7327, or contact the Leukemia and Lymphoma Society's Information Resource Center, 1- 800-955-4572. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.